Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia
Bär, Christian (Telomeres and Telomerase Group)
Povedano, Juan Manuel (Telomeres and Telomerase Group)
Serrano, Rosa (Telomeres and Telomerase Group)
Benítez-Buelga, Carlos (Centro Nacional de Investigaciones Oncológicas)
Popkes, Miriam (Telomeres and Telomerase Group)
Formentini, Ivan (Roche Pharma Research and Early Development)
Bobadilla, Maria (F. Hoffmann-La Roche Ltd)
Bosch i Tubert, Fàtima (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Blasco, María A (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)

Data:	2016
Resum:	Aplastic anemia is a fatal bone marrow disorder characterized by peripheral pancytopenia and marrow hypoplasia. The disease can be hereditary or acquired and develops at any stage of life. A subgroup of the inherited form is caused by replicative impairment of hematopoietic stem and progenitor cells due to very short telomeres as a result of mutations in telomerase and other telomere components. Abnormal telomere shortening is also described in cases of acquired aplastic anemia, most likely secondary to increased turnover of bone marrow stem and progenitor cells. Here, we test the therapeutic efficacy of telomerase activation by using adeno-associated virus (AAV)9 gene therapy vectors carrying the telomerase Tert gene in 2 independent mouse models of aplastic anemia due to short telomeres (Trf1- and Tert-deficient mice). We find that a high dose of AAV9-Tert targets the bone marrow compartment, including hematopoietic stem cells. AAV9-Tert treatment after telomere attrition in bone marrow cells rescues aplastic anemia and mouse survival compared with mice treated with the empty vector. Improved survival is associated with a significant increase in telomere length in peripheral blood and bone marrow cells, as well as improved blood counts. These findings indicate that telomerase gene therapy represents a novel therapeutic strategy to treat aplastic anemia provoked or associated with short telomeres.
Drets:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Blood, Vol. 127, Núm. 14 (April 2016) , p. 1770-1779, ISSN 1528-0020

DOI: 10.1182/blood-2015-08-667485

10 p, 1.5 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats